Accretion dilution is where merger maths meets interview theatre. The mechanics are genuinely simple, the quick rules are learnable in an evening and yet it produced more fumbles in my interviews than any topic except the DCF, because candidates memorise the rules without the machinery underneath. Worse, most walk straight into the conceptual trap at the end. Here is the whole topic, trap included.
What the analysis is
One question: is the acquirer's earnings per share higher or lower after the deal than before? Pro forma earnings over pro forma shares, against the standalone number. Higher is accretive, lower is dilutive. Note what the question is not: it says nothing yet about whether the deal creates value. Hold that thought; it is the trap.
The quick rules
- All-stock deals: compare price-to-earnings ratios. An acquirer buying a target on a lower P/E than its own is accretive, mechanically: it is exchanging expensively priced earnings for cheaply priced ones. Buying a higher P/E dilutes, for the mirror reason.
- All-cash or debt deals: compare yields. The target's earnings yield, its earnings over the price paid, versus the after-tax cost of the cash or debt funding it. Earnings arriving above the funding cost accrete; below, dilute. Never forget the after-tax: interest is deductible and omitting the tax adjustment was the single most common mechanical error I marked.
- Mixed consideration: blend. Weight the two tests by the funding mix. Nothing new, just bookkeeping discipline.
A worked example that reconciles
One deal, two structures · both reconcile with the rules
Acquirer: net income US$100m, 100m shares, EPS US$1.00, share price US$20, so 20x earnings.
Target: net income US$20m, purchased for US$300m of equity value, so 15x paid.
All-stock: issue US$300m of new shares at US$20, which is 15m shares. Pro forma income US$120m over 115m shares gives EPS of about US$1.04: roughly 4% accretive, as the rule predicted, 15x bought with 20x paper.
All-cash instead, borrowed at 5% with a 25% tax rate: after-tax interest is US$11.25m. Pro forma income US$108.75m over the unchanged 100m shares gives EPS of about US$1.09: roughly 9% accretive, because the target's 6.7% earnings yield clears a 3.75% after-tax funding cost.
Two disciplines inside that box carried marks: the after-tax adjustment and using post-deal share counts. Synergies, when given, simply add to pro forma income before the division and forgone interest on cash spent from the balance sheet subtracts, the mirror of the borrowing case.
The trap in the word accretive
Now the question that separated finalists: 'the deal is accretive, is it a good deal?' The reflex answer, yes, fails. Accretion is arithmetic about ratios; value creation is about whether synergies exceed the premium paid. A company can overpay catastrophically and still print accretion, especially with cheap funding and it can strike a brilliantly value-creating deal that dilutes EPS for two years. The scoring answer says exactly that, then adds the honest coda: markets and boards still watch EPS because coverage, compensation and optics are real, which is why the analysis exists at all. That one paragraph, delivered calmly, told me a candidate understood the difference between accounting and economics and it is the same lens the talking-about-a-deal article applies to live transactions.
Where it fits
In interviews, this topic arrives as quick rules, a mental example like the one above and the trap. In modelling tests it becomes a small model with a sensitivity on price and mix, per the modelling tests article and it leans on the equity-versus-enterprise machinery from earlier in this series, since the price paid here is equity value. In the M&A process itself, it is one exhibit among many in a board deck, which the process questions article on this site situates. Learn the rules, rehearse the box aloud and refuse the trap and this is one of the most bankable topics in the stack; having it examined properly is one session of the IBD Recruiting Review.
FAQ
When is an all-stock deal accretive?
When the acquirer buys a target on a lower price-to-earnings ratio than its own: expensively priced earnings exchanged for cheaply priced ones.
When is a cash deal dilutive?
When the after-tax cost of the funding exceeds the target's earnings yield. Forgetting the after-tax adjustment on interest is the most common mechanical error.
Does accretive mean a deal is good?
No. Accretion is ratio arithmetic; value creation is synergies against the premium paid. Deals can be accretive and value-destructive and the reverse.
Former Executive Director in TMT Investment Banking at Nomura and M&A banker at BNP Paribas. Top-rated mentor with 300+ sessions. About
